Abstracts Archive - Page 1662 of 2425 - ACR Meeting Abstracts

Abstract Number: 2849 • 2015 ACR/ARHP Annual Meeting
Apremilast, an Oral Phosphodiesterase 4 Inhibitor, Is Associated with Long-Term (104-Week) Improvement in Fatigue in Patients with Psoriatic Arthritis: Pooled Results from 3 Phase 3, Randomized, Controlled Trials
Arthur Kavanaugh¹, Dafna Gladman², Christopher J. Edwards³, Airi Poder⁴, Frederic Liote⁵, Paul A. Bird⁶, Georg Schett⁷, Melissa McIlraith⁸, Lichen Teng⁸ and Philip J. Mease⁹, ¹University of California, San Diego School of Medicine, LaJolla, CA, ²Toronto Western Research Institute, Toronto, ON, Canada, ³University Hospital Southampton, Southampton, United Kingdom, ⁴Clinical Research Centre Ltd, Tartu, Estonia, ⁵University Paris Diderot, Paris, France, ⁶University of New South Wales, Sydney, Australia, ⁷Department of Internal Medicine 3 and Institute for Clinical Immunology, University of Erlangen-Nuremberg, Erlangen, Germany, ⁸Celgene Corporation, Warren, NJ, ⁹Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Patients (pts) with active psoriatic arthritis (PsA) have disease involvement across multiple domains. Pts can have substantial fatigue, which is increasingly being recognized as…
Abstract Number: 2850 • 2015 ACR/ARHP Annual Meeting
Etanercept Treatment in Psoriatic Arthritis: Need for Co-Medication?
Brigitte Michelsen¹, Dag Magnar Soldal², Arthur Kavanaugh³ and Glenn Haugeberg^1,4,5, ¹Rheumatology, Hospital of Southern Norway Trust, Kristiansand, Norway, ²Rheumatology, Hospital of Southern Norway, Kristiansand, Norway, ³University of California San Diego, La Jolla, CA, ⁴Rheumatology, Martina Hansens Hospital, Gjettum, Norway, ⁵Rheumatology, The Norwegian University of Science and Technology, Trondheim, Norway
Background/Purpose: The role of co-medication e.g. with conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), among patients with psoriatic arthritis (PsA) who are receiving tumor necrosis factor…
Abstract Number: 2851 • 2015 ACR/ARHP Annual Meeting
Anti-TNF Therapy Is Associated with an Increase in Serious Infections in Patients with Spondyloarthritis (SpA), Especially during the First 12 Monts of Treatment: Results from the GISEA Registry
Fabiola Atzeni¹, Marco Sebastiani², Valentina Panetta³, Fausto Salaffi⁴, Antonio Marchesoni⁵, Roberta Ramonda⁶, Florenzo Iannone⁷, Roberto Gorla⁸, Elisa Gremese⁹, Marcello Govoni¹⁰, Pier Carlo Sarzi-Puttini¹¹, Gianfranco Ferraccioli¹², Giovanni Lapadula¹³ and on behalf of GISEA group, ¹Rheumatology Unit, L. Sacco University Hospital of Milan, Milan, Italy, ²SC Reumatologia, Dipartimento di Medicine, Medicina d’Urgenza e Specialità Mediche, Azienda Ospedaliero-Universitaria di Modena, Modena, Italy, ³L'altrastatistica -Consultancy & Training- Biostatistics office., Rome, Italy, ⁴Rheumatology Department, Polytechnic University of Marche, C. Urbani Hospital, Jesi,, Ancona, Italy, ⁵Day Hospital of Rheumatology, G. Pini Orthopedic Institute, Chair of Rheumatology of Milan, Milan, Italy, ⁶Cattedra, Voc Rheumatology, University of Padua, Padova, Italy, ⁷Interdisciplinary Department of Medicine (DIM), Rheumatology Unit, University of Bari, Bari, Italy, ⁸Rheumatology and Immunology Unit, Spedali Civili di Brescia, Brescia, Italy, ⁹Division of Rheumatology, Institute of Rheumatology, Catholic University of the Sacred Heart, Rome, Italy, ¹⁰Department of Medical Sciences, UOC of Rheumatology, Azienda Ospedaliero-Universitaria S. Anna-Ferrara, University of Ferrara, Cona Ferrara, Italy, ¹¹Rheumatology Unit, University Hospital L Sacco, Milan, Italy, ¹²Rheumatology and Internal Medicine, Catholic University of the Sacred Heart, Rome, Italy, ¹³Bari University, Rheumatology, Bari, Italy
Background/Purpose: Infection is by far the most common and most important adverse effect of TNF inhibitors (TNFI) in the treatment of rheumatoid arthritis (RA) and…
Abstract Number: 2853 • 2015 ACR/ARHP Annual Meeting
Secukinumab Improves Skin Symptoms and Physical Functioning Compared with Ustekinumab in Patients with Moderate to Severe Psoriasis with Concomitant Psoriatic Arthritis: Subanalysis of a Randomized, Double Blind, Parallel-Group, Active Comparator-Controlled Phase 3b Trial
Alice B. Gottlieb¹, Diamant Thaci², Andrew Blauvelt³, Marina Milutinovic⁴ and Shephard Mpofu⁴, ¹Tufts Medical Center and Tufts University School of Medicine, Boston, MA, ²Comprehensive Center for Inflammation Medicine, University Hospital Schleswig-Holstein, Lübeck, Germany, ³Research Excellence & Personalized Patient Care, Oregon Medical Research Center, Portland, OR, ⁴Novartis Pharma AG, Basel, Switzerland
Background/Purpose: Psoriatic arthritis (PsA) is a common comorbidity in patients (pts) with psoriasis. In the ongoing Phase 3b CLEAR study (NCT02074982), secukinumab, a fully human…
Abstract Number: 2854 • 2015 ACR/ARHP Annual Meeting
Long-Term Tolerability and Efficacy of Golimumab in Active Nonradiographic Axial Spondyloarthritis: Results from the Open-Label Extension of a Randomized, Double-Blind Study
Désirée van der Heijde¹, Maxime Dougados², Walter Maksymowych³, Gina Bergman⁴, Sean P. Curtis⁴, Anjela Tzontcheva⁴, George Philip⁴, Susan Huyck⁴ and Joachim Sieper⁵, ¹Leiden University Medical Center, Leiden, Netherlands, ²Paris-Descartes University, Paris, France, ³University of Alberta, Edmonton, AB, Canada, ⁴Merck & Co., Inc., Kenilworth, NJ, ⁵University Clinic Benjamin Franklin, Berlin, Germany
Background/Purpose: The tolerability and efficacy of golimumab (GLM) as a treatment for nonradiographic axial spondyloarthritis (nr-axSpA) were recently investigated in a randomized, double-blind (DB), placebo…
Abstract Number: 2855 • 2015 ACR/ARHP Annual Meeting
Non-Response to Antitnf Treatment in Psoriatic Arthritis Can be Predicted By an Objective Automated Measurement of Fluorescence-Signal Intensities in Fluorescence-Optical Imaging Technique – the First Interims Analysis of the Xplore-Study
Michaela Koehm^1,2, Tanja Rossmanith³, Ulf Henkemeier⁴, Peer Aries⁵, Rieke Alten⁶, Hans-Eckhard Langer⁷, Harald Burkhardt^8,9 and Frank Behrens^1,9, ¹Clinical Research, Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ²Rheumatology, Goethe-University Frankfurt, Frankfurt/Main, Germany, ³Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt, Germany, ⁴Centre of Innovative Diagnostics and Therapeutics Rheumatology/Immunology at Goethe-University, Frankfurt, Germany, ⁵Rheumatologie im Struenseehaus, Hamburg, Germany, ⁶Internal Medicine, Rheumatology & Clinical Immunology, Schlosspark-Klinik, University Medicine Berlin, Berlin, Germany, ⁷RHIO (Rheumatology, Immunology, Osteology) Duesseldorf, Duesseldorf, Germany, ⁸Fraunhofer Institute for Molecular Biology and Applied Ecology IME, Project Group Translational Medicine & Pharmacology TMP, Frankfurt/Main, Germany, ⁹Rheumatology, Goethe-University Frankfurt, Frankfurt, Germany
Background/Purpose: Psoriatic arthritis (PsA) is a chronic inflammatory disorder. AntiTNF-therapy is initiated after failure of NSAID and DMARD-treatment. Up to 30-40% of the patients are…
Abstract Number: 2856 • 2015 ACR/ARHP Annual Meeting
Efficacy and Safety of Ustekinumab in Psoriatic Arthritis Patients with Spondylarthritis As Well As Peripheral Arthritis: Results from 2 Phase 3, Multicenter, Double-Blind, Placebo-Controlled Study
Arthur Kavanaugh¹, Luis Puig², Alice B. Gottlieb³, Christopher T. Ritchlin⁴, Yin You⁵, Shu Li⁵, Michael Song⁵, Bruce Randazzo⁵, Proton Rahman⁶ and Iain. B. McInnes⁷, ¹University of California San Diego, La Jolla, CA, ²Universitat Autònoma de Barcelona, Barcelona, Spain, ³Tufts Medical Center, Boston, MA, ⁴Allergy, Immunology and Rheumatololgy Division, University of Rochester Medical Center, Rochester, NY, ⁵Janssen Research & Development, LLC, Spring House, PA, ⁶Rheumatology, Memorial University of Newfoundland, St Johns, NF, Canada, ⁷Institute of Infection, Immunity and Inflammation, College of Medicine, Veterinary Medicine and Life Sciences, University of Glasgow, Glasgow, United Kingdom
Background/Purpose: To evaluate ustekinumab(UST) in a subgroup of psoriatic arthritis (PsA) pts with physician diagnosed spondylarthritis, as well as peripheral arthritis, from the PSUMMIT 1…
Abstract Number: 2857 • 2015 ACR/ARHP Annual Meeting
The 8-Year Retention Rate of the First TNF-Inhibitor in the Treatment of Spondyloarthropathies: Real-Life Data from Three Local Registries
Ennio Giulio Favalli¹, Andrea Becciolini¹, Martina Biggioggero², Enrico Fusaro³, Simone Parisi³, Alarico Ariani⁴, Daniele Santilli⁴, Antonio Marchesoni¹ and Pier Luigi Meroni², ¹Department of Rheumatology, Gaetano Pini Institute, Milan, Italy, ²University of Milan, Department of Clinical Sciences and Community Health, Division of Rheumatology, Gaetano Pini Institute, Milan, Italy, ³Città della salute e della Scienza, Turin, Italy, ⁴Department of Internal Medicine and Rheumatology, University of Parma, Parma, Italy
Background/Purpose: Long-term data on drug survival of TNF inhibitors (TNFi) in the treatment of spondyloarthropathies are still lacking. The aim of the study is to…
Abstract Number: 2858 • 2015 ACR/ARHP Annual Meeting
A Phosphodiesterase 4 Inhibitor for Psoriatic Arthritis: Systematic Review and Meta-Analysis
Ignacio-Alfredo Valerio-Morales¹, Maria A. Lopez-Olivo², Xin Pan³ and Maria E. Suarez-Almazor⁴, ¹Rheumatology, National Institute of Rehablitation, Mexico, Mexico, ²Department of General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX, ³Department of Rheumatology, Shuguang Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China, ⁴General Internal Medicine, The University of Texas, MD Anderson Cancer Center, Houston, TX
Background/Purpose: Inhibition of phosphodiesterase (PDE) family enzymes is now recognized as target to develop new psoriatic arthritis (PsA) drugs. We conducted a systematic review to…
Abstract Number: 2859 • 2015 ACR/ARHP Annual Meeting
Effect of Weight on Efficacy of Certolizumab Pegol in Patients with Axial Spondyloarthritis
Atul A. Deodhar¹, Joachim Sieper², Owen Davies³, Tommi Nurminen⁴ and Philip J. Mease⁵, ¹Division of Arthritis & Rheumatic Diseases, Oregon Health & Science University, Portland, OR, ²University Hospital Charité, Berlin, Germany, ³UCB Pharma, Slough, United Kingdom, ⁴UCB Pharma, Monheim, Germany, ⁵Swedish Medical Center and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Recent studies suggest that patients' (pts') body weight impacts response to anti-TNF treatment in pts with spondyloarthropathies1 including axial spondyloarthritis (axSpA).2 Here we investigate…
Abstract Number: 2860 • 2015 ACR/ARHP Annual Meeting
Clinical Responses in Joint and Skin Outcomes and Patient-Reported Outcomes Are Associated with Increased Productivity in the Workplace and at Home in Psoriatic Arthritis Patients Treated with Certolizumab Pegol
Arthur Kavanaugh¹, Dafna Gladman², Désirée van der Heijde³, Oana Purcaru⁴ and Philip J. Mease⁵, ¹University of California San Diego, La Jolla, CA, ²University of Toronto, Toronto, ON, Canada, ³Leiden University Medical Center, Leiden, Netherlands, ⁴UCB Pharma, Brussels, Belgium, ⁵Rheumatology Research, Swedish Medical Center, Seattle, WA
Background/Purpose: Compared to the general population, patients (pts) with psoriatic arthritis (PsA) suffer greater amounts of disability and substantially lower employment rates.1 Few studies have…
Abstract Number: 2861 • 2015 ACR/ARHP Annual Meeting
Treatment Patterns of Subcutaneous Biologic Agent Use Among Patients with Ankylosing Spondylitis
Sergio Schwartzman¹, Yunfeng Li², Huanxue Zhou³, Vivian Herrera² and Jacqueline B. Palmer², ¹Hospital for Special Surgery, New York, NY, ²Novartis Pharmaceuticals Corporation, East Hanover, NJ, ³KMK Consulting Inc, East Hanover, NJ
Background/Purpose: Ankylosing spondylitis (AS) is characterized by chronic debilitating inflammation of the spine and/or sacroiliac joints. Several biologic agents have been approved for the treatment…
Abstract Number: 2862 • 2015 ACR/ARHP Annual Meeting
Is Anti-TNF Tapering Possible in Patients with Axial Spondyloarthritis? a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa¹, Emilio Martín-Mola¹, Daniel Seoane-Mato³ and Juan D. Cañete⁴, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁴Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: Anti-TNF therapy is successful for achieving low disease activity (LDA) or clinical remission in patients with axial spondyloarhritis (axSpA). Nevertheless, this therapy has not…
Abstract Number: 2863 • 2015 ACR/ARHP Annual Meeting
Discontinuation of Anti-TNF Therapy in Patients with Axial Spondyloarthritis. a Systematic Literature Review
Victoria Navarro-Compán¹, Chamaida Plasencia-Rodriguez², Eugenio De Miguel¹, Alejandro Balsa³, Emilio Martín-Mola¹, Daniel Seoane-Mato⁴ and Juan D. Cañete⁵, ¹Rheumatology, University Hospital La Paz, Madrid, Spain, ²Rheumatology Department, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ³Rheumatology, La Paz University Hospital-Rheumatology Department, Madrid, Spain, ⁴Research Unit, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology, Hospital Clinic and IDIBAPS, Barcelona, Spain
Background/Purpose: In patients with axial spondyloarthritis (axSpA), anti-TNF therapy is successful for clinically improving signs and symptoms of the disease. However, there is no clear…
Abstract Number: 2864 • 2015 ACR/ARHP Annual Meeting
Long-Term Work Productivity Improvement Associated with Apremilast, an Oral Phosphodiesterase 4 Inhibitor, in Patients with Psoriatic Arthritis: Pooled Analysis of 3 Phase 3 Studies
Frank Zhang¹, Zoe Clancy² and Stan Li³, ¹Pricing and Market Access, I&I, Celgene Corporation, Warren, NJ, ²33 Technology Drive, Celgene Corporation, Warren, NJ, ³Celgene Corporation, Warren, NJ
Background/Purpose: Studies have shown that patients with psoriatic arthritis (PsA) have significantly compromised physical health and quality of life, and negative effect on work productivity…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].